Type 2 Diabetes Medications: Mechanisms, Classes, and Selection Guide
Pharmacologic Toolkit for T2D: Matching Drug to Patient
Nine major drug classes target distinct pathophysiologic defects. Selection follows ADA/EASD 2024 algorithm: prioritize cardio-renal protection, hypoglycemia risk, weight effect, cost, and patient preference.
Mechanism-Based Classification
| Class | Key Agents | Primary Mechanism | Weight | Hypo Risk | Cardio-Renal Benefit |
|---|---|---|---|---|---|
| Biguanide | Metformin | ↓ Hepatic gluconeogenesis; ↑ insulin sensitivity (AMPK) | Neutral/↓ | None | CV neutral (UKPDS legacy) |
| Sulfonylureas | Glipizide, glimepiride, glyburide | ↑ Insulin secretion (KATP closure) | ↑ 2–4 kg | Moderate | Neutral |
| Meglitinides | Repaglinide, nateglinide | Rapid, short-acting insulin secretion | ↑ | Low (short action) | Neutral |
| TZDs | Pioglitazone, rosiglitazone | PPAR-γ agonist → ↑ insulin sensitivity (adipose) | ↑ 3–5 kg | Low | Pioglitazone: ↓ stroke, ↑ HF |
| DPP-4i | Sitagliptin, linagliptin, saxagliptin, alogliptin | ↑ GLP-1/GIP (inhibit degradation) | Neutral | None | Neutral (saxagliptin/alogliptin: ↑ HF hosp) |
| SGLT2i | Empagliflozin, dapagliflozin, canagliflozin, ertugliflozin | ↓ Renal glucose reabsorption → glycosuria | ↓ 2–3 kg | None (mono) | Strong: ↓ MACE, HF hosp, CKD progression |
| GLP-1 RA | Semaglutide, liraglutide, dulaglutide, tirzepatide (GIP/GLP-1) | ↑ Insulin, ↓ glucagon, ↓ gastric emptying, ↑ satiety | ↓↓ 5–15% | None (mono) | Strong: ↓ MACE, CKD (some) |
| Alpha-glucosidase inhibitors | Acarbose, miglitol | Delay carb absorption (gut) | Neutral/↓ | None | Neutral |
| Bile acid sequestrant | Colesevelam | ↑ GLP-1, ↓ hepatic glucose | Neutral | None | LDL ↓; CV neutral |
| Dopamine-2 agonist | Bromocriptine QR | Central circadian reset | Neutral | None | Neutral |
Selection Algorithm (Simplified)
- ASCVD / high CV risk / CKD / HF: Start SGLT2i or GLP-1 RA with proven benefit (even if HbA1c near target).
- Need weight loss: GLP-1 RA > SGLT2i > metformin.
- Hypoglycemia avoidance critical: Avoid SU/meglitinide/insulin; prefer SGLT2i, GLP-1 RA, DPP-4i, metformin, TZD.
- Cost/access barriers: Metformin → SU (glipizide) → basal insulin (NPH/glargine biosimilar).
- Renal impairment: Dose-adjust per eGFR. Linagliptin (no adjust), SGLT2i approved down to eGFR 20 (dapagliflozin/empagliflozin).
- Injection aversion: Oral agents first; oral semaglutide (Rybelsus) now available.
Combination Principles
- Complementary mechanisms (e.g., metformin + SGLT2i + GLP-1 RA = "triple therapy" with additive efficacy, low hypo, weight loss, organ protection).
- Avoid SU + insulin (high hypo) unless necessary.
- De-intensify if HbA1c <6.5% with hypoglycemia risk (elderly, CKD).
Emerging: Tirzepatide (GIP/GLP-1 Dual Agonist)
SURPASS/SURMOUNT trials: HbA1c ↓ 2.0–2.3%, weight ↓ 15–22%. Approved T2D (2022) & obesity (2023). Redefines efficacy ceiling.
Prescribing pearl: Start low, go slow, counsel on GI side effects (GLP-1 RA), genital mycotic infections (SGLT2i), euglycemic DKA risk (SGLT2i — educate on sick days, low-carb, alcohol).
Diabetes - Related Articles
- Understanding Normal Blood Sugar Readings: A Comprehensive Guide
- Understanding the Types of Diabetes: Type 1, Type 2 & Gestational
- Insulin Pump Therapy for Diabetes: Guidelines & Information
- Understanding Diabetes Diet Compliance: Key Factors
- Januvia (Sitagliptin): Side Effects, Uses & Precautions
- Best Carbs for Diabetes: A Guide to Blood Sugar Management
- Reusing Diabetic Test Strips: Risks & Why It's Not Recommended
